A review of endocrine changes in anorexia nervosa

Journal of Psychiatric Research

Volumn 33, Issue 2, 1999, Pages 139-152

  Stoving R K ^a   Hangaard, J ^a   Hansen Nord, M ^a   Hagen, C ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; CORTICOTROPIN RELEASING FACTOR; GROWTH HORMONE; LEPTIN; MONOAMINE; NEUROPEPTIDE; NEUROPEPTIDE Y; PROOPIOMELANOCORTIN; SEROTONIN; SOMATOMEDIN C;

AMENORRHEA; ANOREXIA NERVOSA; ENDOCRINE SYSTEM; FOOD INTAKE; GROWTH HORMONE RELEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; PRIORITY JOURNAL; REVIEW;

EID: 0033011765     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(98)00049-1     Document Type: Article

References (215)

1. Abraham SF, Beumont PJ, Cobbin DM. Catecholamine metabolism and body weight in anorexia nervosa. British Journal of Psychiatry 1981;138:244-47.
2. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos Flier E, Flier JS. Role of leptin in the neuroendocrine response to fasting. Nature 1996;382:250-52.
3. Allouche J, Bennet A, Barbe P, Plantavid M, Caron P, Louvet JP. LH pulsatility and in vitro bioactivity in women with anorexia nervosa-related hypothalamic amenorrhea. Acta Endocrinologica Copenhagen 1991;125:614-20.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV; Washington DC: American Psychiatric Press, 1994.
5. Andersen AN, Hagen C, Lange P, Boesgaard S, Djursing H, Eldrup E, Micic S. Dopaminergic regulation of gonadotropin levels and pulsatility in normal women. Fertility and Sterility 1987;47:391-97.
6. Arase K, York DA, Shimizu H, Shargill N, Bray GA. Effects of corticotropin-releasing factor on food intake and brown adipose tissue thermogenesis in rats. American Journal of Physiology 1988;255:E255-59.
7. Argente J, Caballo N, Barrios V, Munoz MT, Pozo J, Chowen JA, Morande G, Hernandez M. Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in patients with anorexia nervosa: Effects of short- and long-term weight recuperation. Journal of Clinical Endocrinology and Metabolism 1997;82:2084-92.
8. Armeanu MC, Berkhout GM, Schoemaker J. Pulsatile luteinizing hormone secretion in hypothalamic amenorrhea, anorexia nervosa, and polycystic ovarian disease during naltrexone treatment. Fertility and Sterility 1992;57:762-70.
9. Baez L. Role of catecholamines in the anorectic effects of amphetamine in rats. Psychopharmacologia 1974;35:91-8.
10. Bando H, Yamasaki R, Saito S. Evaluation of hypothalamic-pituitary function in a combination of tests with four hypothalamic releasing hormones and L-dopa in normal subjects and in patients with hypothalamic and/or pituitary disorders. Endocrinology Japan 1989;36:705-20.
11. Bannai C, Kuzuya N, Koide Y, Fujita T, Itakura M, Kawai K, Yamashita K. Assessment of the relationship between serum thyroid hormone levels and peripheral metabolism in patients with anorexia nervosa. Endocrinology Japan 1988;35:455-62.
12. Baranowska B. Are disturbances in opioid and adrenergic systems involved in the hormonal dysfunction of anorexia nervosa? Psychoneuroendocrinology 1990;15:371-79.
13. Barry VC, Klawans HL. On the role of dopamine in the pathophysiology of anorexia nervosa. Journal of Neural transmission 1976;38:107-22.
14. Baxter CB. Acquired growth hormone insensitivity and insulin-like growth factor I bioavailability. Endocrinology and Metabolism 1997;4:65-9.
15. Baxter RC. Molecular aspects of insulin-like growth factor binding proteins. In: LeRoith D, editor. Advances in Molecular and Cellular Endocrinology. JAI Press, 1996. P. 123-59
16. Bentham J, Rodriguez Arnao J, Ross RJ. Acquired growth hormone resistance in patients with hypercatabolism. Hormone Research 1993;40:87-91.
17. Bergh C, Södersten P. Anorexia nervosa: rediscovery of a disorder. Lancet 1998;351:1427-29.
18. Biederman J, Herzog DB, Rivinus TM, Ferber RA, Harper GP, Orsulak PJ, Harmatz JS, Schildkraut JJ. Urinary MHPG in anorexia nervosa patients with and without a concomitant major depressive disorder. Journal of Psychiatric Research 1984;18:149-60.
19. Blickle JF, Reville P, Stephan F, Meyer P, Demangeat C, Sapin R. The role of insulin, glucagon and growth hormone in the regulation of plasma glucose and free fatty acid levels in anorexia nervosa. Hormone Metabolism Research 1984;16:336-40.
20. Blouin AG, Blouin JH, Perez EL, Bushnik T, Zuro C, Mulder E. Treatment of bulimia with fenfluramine and desipramine. Journal of Clinical Psychopharmacology 1988;8:261-69.
21. Boyar RM, Hellman LD, Roffwarg H, Katz J, Zumoff B, O'Connor J, Bradlow HL, Fukushima DK. Cortisol secretion and metabolism in anorexia nervosa. The New England Journal of Medicine 1977;296:190-93.
22. Brambilla F, Lampertico M, Sali L, Cavagnini F, Invitti C, Maggioni M, Candolfi C, Panerai AE, Muller EE. Clonidine stimulation in anorexia nervosa: growth hormone, cortisol, and β-endorphin responses. Psychiatry Research1987;20:19-31.
23. Brambilla F, Ferrari E, Petraglia F, Facchinetti F, Catalano M, Genazzani AR. Peripheral opioid secretory pattern in anorexia nervosa. Psychiatry Research 1991;39:115-27.
24. Brauman H, Gregoire F. The growth hormone response to insulin induced hypoglycaemia in anorexia nervosa and control underweight or normal subjects. European Journal of Clinical Investigation 1975;5:289-95.
25. Brewerton TD, Mueller EA, Brandt HA, Lesem MD, Murphy DL, Jimerson DC. Evidence for serotonin dysregulation in anorexia nervosa. Scientific Proceedings of the American Psychiatric Association 1987;140:NR195.
26. Broocks A, Liu J, Pirke KM. Semistarvation-induced hyperactivity compensates for decreased norepinephrine and dopamine turnover in the mediobasal hypothalamus of the rat. Journal of Neural Transmission 1990;79:113-24.
27. Buvat J, Buvat Herbaut M, Lemaire A, Racadot A, Fourlinnie JC. Comparison of estrogen priming effects with body weight restoration effects on the gonadotropin pattern of patients with anorexia nervosa. Hormone Research 1984;20:224-30.
28. Byrne TA, Morrissey TB, Gatzen C, Benfell K, Nattakom TV, Scheltinga MR, LeBoff MS, Ziegler TR, Wilmore DW. Anabolic therapy with growth hormone accelerates protein gain in surgical patients requiring nutritional rehabilitation. Annals of Surgery 1993;218:400-16.
29. Chehab FF, Lim ME, Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nature Genetics 1996;12:318-20.
30. Cioffi WG, Gore DC, Rue LW, 3rd, Carrougher G, Guler HP, McManus WF, Pruitt BA. Insulin-like growth factor-1 lowers protein oxidation in patients with thermal injury. Annals of Surgery 1994;220:310-16.
31. Coleman DL. Obese and diabetes: Two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 1978;14:141-48.
32. Considine RV, Considine EL, Williams CJ, Hyde TM, Caro JF. The hypothalamic leptin receptor in humans. Identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa rat mutations. Diabetes 1996a;19:992-94.
33. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF. Serum immunoreactive-leptin concentrations in normal-weight and obese humans ⌊see comments⌋. The New England Journal of Medicine 1996b;334:292-95.
34. Coplan JD, Andrews MW, Rosenblum LA, Owens MJ, Friedman S, Gorman JM, Nemeroff CB. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult non-human primates exposed to early-life Stressors: implications for the pathophysiology of mood and anxiety disorders. Proceedings of the National Academy of Sciences of the United States of America 1996;93:1619-23.
35. Coppen AJ, Gupta RK, Eccleston EG, Wood KM, Wakeling A. Plasma-tryptophan in anorexia nervosa. Lancet 1976;??,961.
36. Counts DR, Gwirtsman H, Carlsson LM, Lesem M, Cutler GB. The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors IGFs, and the IGF binding proteins. Journal of Clinical Endocrinology and Metabolism1992;75:762-67.
37. Croxson MS, Ibbertson HK. Low serum triiodothyronine T3; and hypothyroidism in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 1977;44:167-74.
38. Dally PJ, Sargant WA. A new treatment of anorexia nervosa. British Medical Journal 1960;1770-73.
39. Davenport ML, Isley WL, Pucilowska JB, Pemberton LB, Lyman B, Underwood LE, Clemmons DR. Insulin-like growth factor binding protein-3 proteolysis is induced after elective surgery. Journal of Clinical Endocrinology and Metabolism 1992;75:590-95.
40. Davies SC, Wass JA, Ross RJ, Cotterill AM, Buchanan CR, Coulson VJ, Holly JM. The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. Journal of Endocrinology 1991;130:469-73.
41. de Rosa G, Corsello SM, de Rosa E, Della Casa S, Ruffilli MP, Grasso P, Pasargiklian E. Endocrine study of anorexia nervosa. Experimental and Clinical Endocrinology 1983;82:160-72.
42. DeVile CJ, Sufraz R, Lask BD, Stanhope R. Occult intracranial tumours masquerading as early onset anorexia nervosa. British Medical Journal 1995;311:1359-60.
43. Djursing H, Hagen C, Andersen AN, Nyholm HC, Petersen K. Prolonged dopamine receptor blockade in normoprolactinemic amenorrhea: a double-blind placebo study. Fertility and Sterility 1986;46:840-45.
44. Doerr P, Fichter M, Pirke KM, Lund R. Relationship between weight gain and hypothalamic pituitary adrenal function in patients with anorexia nervosa. Journal of Steroid Biochemistry 1980;13:529-37.
45. Dourish CT, Rycroft W, Iversen SD. Postponement of satiety by blockade of brain cholecystokinin CCK-B; receptors. Science 1989;245:1509-11.
46. Drewnowski A, Krahn DD, Demitrack MA, Nairn K, Gosnell BA. Taste responses and preferences for sweet high-fat foods: evidence for opioid involvement. Physiology and Behavior 1992;51:371-79.
47. Erickson JC, Clegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996;381:415-18.
48. Falk JR, Halmi KA. Amenorrhea in anorexia nervosa: examination of the critical body weight hypothesis. Biological Psychiatry 1982;17:799-806.
49. Ferrari E, Fraschini F, Brambilla F. Hormonal circadian rhythms in eating disorders. Biological Psychiatry 1990;27:1007-20.
50. Fichter MM, Doerr P, Pirke KM, Lund R. Behavior, attitude, nutrition and endocrinology in anorexia nervosa. Acta Psychiatrica Scandinavica 1982;66:429-44.
51. Fichter MM, Pirke KM, Holsboer F. Weight loss causes neuroendocrine disturbances: experimental study in healthy starving subjects. Psychiatry Research 1986;17:61-72.
52. Fombonne E. Anorexia nervosa. No evidence of an increase. British Journal of Psychiatry 1995;166:462-71.
53. Frisch RE, McArthur JW. Menstrual cycles: fatness as a determinant of minimum weight for height necessary for their maintenance or onset. Science 1974;185:949-51.
54. Frystyk J, Dinesen B, Orskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regulation 1995;5:169-76.
55. Garcia Rubi E, Vazquez Aleman D, Mendez JP, Salinas JL, Garza Flores J, Ponce de Leon S, Perez Palacios G, Ulloa Aguirre A. The effects of opioid blockade and GnRH administration upon luteinizing hormone secretion in patients with anorexia nervosa during the stages of weight loss and weight recovery. Clinical Endocrinology 1992;37:520-28.
56. Genazzani AD, Petraglia F, Gastaldi M, Volpogni C, Gamba O, Genazzani AR. Naltrexone treatment restores menstrual cycles in patients with weight loss-related amenorrhea. Fertility and Sterility 1995;64:951-56.
57. Genazzani AR, Genazzani AD, Volpogni C, Pianazzi F, Li GA, Surico N, Petraglia F. Opioid control of gonadotrophin secretion in humans. Human Reproduction 1993;8 Suppl 2:151-53.
58. Geracioti TD, Jr., Liddle RA, Altemus M, Demitrack MA, Gold PW. Regulation of appetite and cholecystokinin secretion in anorexia nervosa. American Journal of Psychiatry 1992;149:958-61.
59. Gerner RH, Gwirtsman HE. Abnormalities of dexamethasone suppression test and urinary MHPG in anorexia nervosa. American Journal of Psychiatry 1981;138:650-53.
60. Gerner RH, Yamada T. Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. Brain Research 1982;238:298-302.
61. Ghigo E, Arvat E, Gianotti L, Nicolosi M, Valetto MR, Avagnina S, Bellitti D, Rolla M, Muller EE, Camanni F. Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa. Biological Psychiatry 1994;36:689-695.
62. Gillberg C. Low dopamine and serotonin levels in anorexia nervosa ⌊letter⌋. American Journal of Psychiatry 1983;140:948-49.
63. Giusti M, Torre R, Traverso L, Cavagnaro P, Attanasio R, Giordano G. Endogenous opioid blockade and gonadotropin secretion: role of pulsatile luteinizing hormone-releasing hormone administration in anorexia nervosa and weight loss amenorrhea. Fertility and Sterility 1988;49:797-801.
64. Gold PW, Gwirtsman H, Avgerinos PC, Nieman LK, Gallucci WT, Kaye W, Jimerson D, Ebert M, Rittmaster R, Loriaux DL, et al., Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients. The New England Journal of Medicine 1986;314:1335-42.
65. Goldberg SG, Halmi KA, Eckert ED. Cyproheptadine in anorexia nervosa. British Journal of Psychiatry 1996;134:67-70.
66. Golden NH, Shenker IR. Amenorrhea in anorexia nervosa. Neuroendocrine control of hypothalamic dysfunction. International Journal of Eating Disorders 1994;16:53-60.
67. Goldman CK, Marino L, Leibowitz SF. Postsynaptic α2-noradrenergic receptors mediate feeding induced by paraventricular nucleus injection of norepinephrine and clonidine. European Journal of Pharmacology 1985;115:11-9.
68. Goodwin GM, Shapiro CM, Bennie J, Dick H, Carroll S, Fink G. The neuroendocrine responses and psychological effects of infusion of L-tryptophan in anorexia nervosa. Psychological Medicine 1989;19:857-64.
69. Gosnell BA, Morley JE, Levine AS. Adrenal modulation of the inhibitory effect of corticotropin releasing factor on feeding. Peptides 1983;4:807-12.
70. Gross HA, Lake CR, Ebert MH, Ziegler MG, Kopin IJ. Catecholamine metabolism in primary anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 1979;49:805-9.
71. Grossman A, Moult PJ, McIntyre H, Evans J, Silverstone T, Rees LH, Besser GM. Opiate mediation of amenorrhoea in hyperprolactinaemia and in weight-loss related amenorrhoea. Clinical Endocrinology 1982;17:379-88.
72. Gwirtsman HE, Roy Byrne P, Yager J, Gerner RH. Neuroendocrine abnormalities in bulimia. American Journal of Psychiatry 1983;140:559-63.
73. Gwirtsman HE, Kaye WH, George DT, Jimerson DC, Ebert MH, Gold PW. Central and peripheral ACTH and cortisol levels in anorexia nervosa and bulimia. Archives of General Psychiatry 1989;46:61-9.
74. Halmi KA. Anorexia nervosa: recent investigations. Annual Review of Medicine 1978a;29:137-48.
75. Halmi KA, Dekirmenjian H, Davis JM, Casper R, Goldberg S. Catecholamine metabolism in anorexia nervosa. Archives of General Psychiatry 1978b;35:458-60.
76. Hamilton J. A question of rhythm: recent advances in growth hormone research. Canadian Medical Association Journal 1995;153:585-8.
77. Hangaard J, Andersen M, Grodum E, Koldkjær O, Hagen C. Pulsatile thyrotropin secretion in patients with Addisons disease during variable gluccocorticoid therapy. Journal of Clinical Endocrinology and Metabolism 1996;81:2502-7.
78. Haraguchi K, Aida K, Akasu F, Takazawa K, Onaya T. Iodide-induced hypothyroidism in a patient with anorexia nervosa. Endocrinology Japan 1986;33:61-5.
79. Harty RF, Pearson PH, Solomon TE, McGuigan JE. Cholecystokinin, vasoactive intestinal peptide and peptide histidine methionine responses to feeding in anorexia nervosa. Regulatory Peptides 1991;36:141-50.
80. Hassanyeh F, Marshall EF. Measures of serotonin metabolism in anorexia nervosa. Acta Psychiatrica Scandinavica 1991;84:561-3.
81. Hebebrand J, van der Heyden J, Devos R, Kopp W, Herpertz S, Remschmidt H, Herzog W. Plasma concentrations of obese protein in anorexia nervosa ⌊letter⌋. Lancet 1995;346:1624-5.
82. Hebebrand J, Blum WF, Barth N, Coners H, Englaro P, Juul A, Ziegler A, Warnke A, Rascher W, Remschmidt H. Leptin levels in patients with anorexia nervosa are reduced in the acute stage and elevated upon short-term weight restoration ⌊see comments⌋. Molecular Psychiatry 1997;2:330-4.
83. Heinrichs SC, Menzaghi F, Pich EM, Baldwin HA, Rassnick S, Britton KT, Koob GF. Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. Neuropsychopharmacology 1994;11:179-86.
84. Herington AC, Ymer S, Stevenson J. Identification and characterization of specific binding proteins for growth hormone in normal sera. Journal of Clinical Investigation 1986;77:1817-23.
85. Heron GB, Johnston DA. Hypothalamic tumor presenting as anorexia nervosa. American Journal of Psychiatry 1976;133:580-2.
86. Herpertz Dahlmann B, Remschmidt H. ⌊The prognostic value of the dexamethasone suppression test for the course of anorexia nervosa - comparison with depressive diseases⌋. Zeitschrift Kinder Jugenpsychiatrie 1990;18:5-11.
87. Hidalgo Rodrigo MI, Diaz Gonzalez RJ, Cabranes Diaz JA, Hidalgo Rodrigo MA, Santiago Guervos M. ⌊Clinical application of the dexamethasone suppression test in the differentiation of subgroups in anorexia nervosa⌋. Actas Luso - Espanolas De Neurologia, Psiquiatria y Ciencias Afines 1991;19:115-21.
88. Hill KK, Bucuvalas J, McClain C, Krycio R, Alfaro MP, Maloney MJ. Growth hormone treatment in anorexia nervosa (Abstract). Annual Meeting American Psychiatric Association. San Diego, California, USA, May 1997.
89. Hinney A, Barth N, Ziegler A, von Prittwitz S, Hamann A, Hennighausen K, Pirke KM, Heils A, Rosenkranz K, Roth H, Coners H, Mayer H, Herzog W, Siegfried A, Lehmkuhl G, Poustka F, Schmidt MH, Schafer H, Grzeschik KH, Lesch KP, Lentes KU, Remschmidt H, Hebebrand J. Serotonin transporter gene-linked polymorphic region: allele distributions in relationship to body weight and in anorexia nervosa. Life Sciences 1997a;61:PL 295-303.
90. Hinney A, Lentes KU, Rosenkranz K, Barth N, Roth H, Ziegler A, Hennighausen K, Coners H, Wurmser H, Jacob K, Romer G, Winnikes U, Mayer H, Herzog W, Lehmkuhl G, Poustka F, Schmidt MH, Blum WF, Pirke KM, Schafer H, Grzeschik KH, Remschmidt H, Hebebrand J. β3-adrenergic-receptor allele distributions in children, adolescents and young adults with obesity, underweight or anorexia nervosa. International Journal of Obesity 1997b;21:224-30.
91. Hinney A, Ziegler A, Nothen MM, Remschmidt H, Hebebrand J. 5-HT2A receptor gene polymorphisms, anorexia nervosa, and obesity ⌊letter⌋. Lancet 1997c;350:1324-5.
92. Hochberg Z, Hertz P, Colin V, Ish Shalom S, Yeshurun D, Youdim MB, Amit T. The distal axis of growth hormone GH; in nutritional disorders: GH-binding protein, insulin-like growth factor-I IGF-I; and IGF-I receptors in obesity and anorexia nervosa. Metabolism 1992;41:106-12.
93. Hoek HW. The incidence and prevalence of anorexia nervosa and bulimia nervosa in primary care. Psychological Medicine 1991;21:455-60.
94. Hotta M, Shibasaki T, Masuda A, Imaki T, Demura H, Ling N, Shizume K. The responses of plasma adrenocorticotropin and cortisol to corticotropin-releasing hormone CRH; and cerebrospinal fluid immunoreactive CRH in anorexia nervosa patients. Journal of Clinical Endocrinology and Metabolism 1986;62:319-24.
95. Hulsey MG, Pless CM, Martin RJ. ICV administration of anti-corticotropin-releasing factor antisense oligonucleotide: effects on feeding behavior and body weight. Regulatory Peptides 1995;59:241-6.
96. Hurd HP, Palumbo PJ, Gharib H. Hypothalamic-endocrine dysfunction in anorexia nervosa. Mayo Clinical Proceedings 1977;52:711-6.
97. Imaki T, Shibasaki T, Hotta M, Demura H. Intracerebroventricular administration of corticotropin releasing factor induces c-fos mRNA expression in brain regions related to stress responses: comparison with pattern of c-fos mRNA induction after stress. Brain Research 1993;616:114-25.
98. Imaki T, Xiao Quan W, Shibasaki T, Yamada K, Harada S, Chikada N, Naruse M, Demura H. Stress induced activation of neuronal activity and corticotropin-releasing factor gene expression in the paraventricular nucleus is modulated by glucocorticoids in rats. Journal of Clinical Investigation 1995;96:231-8.
99. Jeuniewic N, Brown GM, Garfinkel PE, Moldofsky H. Hypothalamic function as related to body weight and body fat in anorexia nervosa. Psychosomatic Medicine 1978;40:187-98.
100. Jhanwar-Uniyal M, Woods JS, Levin BE, Leibowitz SF. Cannula mapping and biochemical studies of hypothalamic opiate and noradrenergic systems in relation to eating behavior. Proceedings of East Psychologic Association 1984;55:106.
101. Joergensen J. The epidemiology of eating disorders in fyn County, Denmark, 1977-86. Acta Psychiatrica Scandinavica 1992;85:30-4.
102. Johnston JL, Leiter LA, Burrow GN, Garfinkel PE, Anderson GH. Excretion of urinary catecholamine metabolites in anorexia nervosa: effect of body composition and energy intake. American Journal of Clinical Nutrition 1984;40:1001-6.
103. Jorgensen JO, Moller J, Laursen T, Orskov H, Christiansen JS, Weeke J. Growth hormone administration stimulates energy expenditure and extrathyroidal conversion of thyroxine to triiodothyronine in a dose-dependent manner and suppresses circadian thyrotrophin levels: studies in GH-deficient adults. Clinical Endocrinology 1994;41:609-14.
104. Kalra SP, Dube MG, Sahu A, Phelps CP, Kalra PS. Neuropeptide Y secretion increases in the para ventricular nucleus in association with increased appetite for food. Proceedings of the National Academy of Sciences of the United States of America 1991;88:10931-5.
105. Katz JL, Boyar RM, Roffwarg H, Hellman L, Weiner H. LHRH responsiveness in anorexia nervosa: intactness despite prepubertal circadian LH pattern. Psychosomatic Medicine 1977;39:241-51.
106. Kaye WH, Ebert MH, Raleigh M, Lake R. Abnormalities in CNS monoamine metabolism in anorexia nervosa. Archives of General Psychiatry 1984;41:350-5.
107. Kaye WH, Berrettini WH, Gwirtsman HE, Gold PW, George DT, Jimerson DC, Ebert MH. Contribution of CNS neuropeptide NPY, CRH, and β-endorphin;alterations to psychophysiological abnormalities in anorexia nervosa. Psychopharmacology Bulletin 1989;25:433-8.
108. Kaye WH, Berrettini W, Gwirtsman H, George DT. Altered cerebrospinal fluid neuropeptide Y and peptide YY immunoreactivity in anorexia and bulimia nervosa. Archives of General Psychiatry 1990;47:548-56.
109. Kaye WH, Gwirtsman HE, George DT, Ebert MH. Altered serotonin activity in anorexia nervosa after long-term weight restoration. Does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior? Archives of General Psychiatry 1991a;48:556-62.
110. Kaye WH, Weltzin TE, Hsu LK, Bulik CM. An open trial of fluoxetine in patients with anorexia nervosa. Journal of Clinical Psychiatry 1991b;52:464-71.
111. Kiriike N, Nishiwaki S, Izumiya Y, Maeda Y, Kawakita Y. Thyrotropin, prolactin, and growth hormone responses to thyrotropin-releasing hormone in anorexia nervosa and bulimia. Biological Psychiatry 1987;22:167-76.
112. Kiyohara K, Tamai H, Takaichi Y, Nakagawa T, Kumagai LF. Decreased thyroidal triiodothyronine secretion in patients with anorexia nervosa: influence of weight recovery. American Journal of Clinical Nutrition 1989;50:767-72.
113. Klawans HL, Margolin DI. Amphetamine-induced hypersensitivity in guinea pigs. Implications in psychosis and human movement disorders. Archives of General Psychiatry 1975;32:725-32.
114. Kling MA, Demitrack MA, Whitfield HJ, Jr., Kalogeras KT, Listwak SJ, DeBellis MD, Chrousos GP, Gold PW, Brandt HA. Effects of the glucocorticoid antagonist RU 486 on pituitary-adrenal function in patients with anorexia nervosa and healthy volunteers: enhancement of plasma ACTH and cortisol secretion in underweight patients. Neuroendocrinology 1993;57:1082-91.
115. Kontula K, Andersson LC, Huttunen M, Pelkonen R. Reduced level of cellular glucocorticoid receptors in patients with anorexia nervosa. Hormone Metabolism Research 1982;14:619-20.
116. Koob GF, Bloom FE. Corticotropin-releasing factor and behavior. Federation Proceedings 1985;44:259-63.
117. Kopp W, Blum WF, von Prittwitz S, Ziegler A, Lubbert H, Emons G, Herzog W, Herpertz S, Deter HC, Remschmidt H, Hebebrand J. Low leptin levels predict amenorrhea in underweight and eating disordered females ⌊see comments⌋. Molecular Psychiatry 1997;2:335-40.
118. Krahn DD, Gosnell BA, Grace M, Levine AS. CRF antagonist partially reverses CRF- and stress-induced effects on feeding. Brain Research Bulletin 1986;17:285-9.
119. Krahn DD, Gosnell BA, Levine AS, Morley JE. Behavioral effects of corticotropin-releasing factor: localization and characterization of central effects. Brain Research 1988;443:63-9.
120. Krahn DD, Gosnell BA, Majchrzak MJ. The anorectic effects of CRH and restraint stress decrease with repeated exposures. Biological Psychiatry 1990;27:1094-102.
121. Krahn DD, Gosnell BA. Corticotropin-releasing hormone: possible role in eating disorders. Psychiatric Medicine 1989;7:235-45.
122. Lanthier D, Stanley BG, Leibowitz SF. Feeding elicted by central morphine injection: sites of action in the brain. Proceedings of East Psychological Associations 1985;56:30.
123. Laughlin GA, Yen SSC. Hypoleptinemia in women athletes: Absence of a diurnal rhythm with amenorrhea. Journal of Clinical Endocrinology and Metabolism 1997;82:318-21.
124. Lecomte P, Kabir Gros N, Lansac J. ⌊Gonadal function in anorexia nervosa patients in the postcritical phase⌋. Annual Endocrinology Paris 1984;45:397-401.
125. Leibowitz SF, Brown O, Tretter JR, Kirschgessner A. Norepinephrine, clonidine, and tricyclic antidepressants selectively stimulate carbohydrate ingestion through noradrenergic system of the paraventricular nucleus. Pharmacology, Biochemistry and Behavior 1985;23:541-50.
126. Leibowitz SF, Sladek C, Spencer L, Tempel D. Neuropeptide Y, epinephrine and norepinephrine in the paraventricular nucleus: stimulation of feeding and the release of corticosterone, vasopressin and glucose. Brain Research Bulletin 1988;21:905-12.
127. Leibowitz SF, Weiss GF, Walsh UA, Viswanath D. Medial hypothalamic serotonin: role in circadian patterns of feeding and macronutrient selection. Brain Research 1989;503:132-40.
128. Leibowitz SF, Weiss GF, Suh JS. Medial hypothalamic nuclei mediate serotonin's inhibitory effect on feeding behavior. Pharmacology, Biochemistry and Behavior 1990;37:735-42.
129. Leibowitz SF, Alexander JT, Cheung WK, Weiss GF. Effects of serotonin and the serotonin blocker metergoline on meal patterns and macronutrient selection. Pharmacology, Biochemistry and Behavior 1993;45:185-94.
130. Lesem MD, George DT, Kaye WH, Goldstein DS, Jimerson DC. State-related changes in norepinephrine regulation in anorexia nervosa. Biological Psychiatry 1989;25:509-12.
131. Liu JP, Clarke IJ, Funder JW, Engler D. Studies of the secretion of corticotropin-releasing factor and arginine vasopressin into the hypophysial-portal circulation of the conscious sheep. II. The central noradrenergic and neuropeptide Y pathways cause immediate and prolonged hypothalamic-pituitary-adrenal activation. Potential involvement in the pseudo-Cushing's syndrome of endogenous depression and anorexia nervosa. Journal of Clinical Investigation 1994;93:1439-50.
132. Lomeo A, Mazzocchi G, Sessarego P, Torre R, Delmonte P, Giusti M. Growth hormone and prolactin response to growth hormone-releasing in anorexia nervosa. Recenti Progressi in Medicina 1989;80:569-73.
133. Loosen PT. The TRH-induced TSH response in psychiatric patients: a possible neuroendocrine marker. Psychoneuroendocrinology 1985;10:237-60.
134. Maas JW, Landis DH. The metabolism of circulatory norepinephrine by human subjects. Journal of Pharmacology and Experimental Therapeutics 1971;177:600-12.
135. Maeda K, Kato Y, Yamaguchi N, Chihara K, Ohgo S. Growth hormone release following thyrotrophin releasing hormone injection into patients with anorexia nervosa. Acta Endocrinologica Copenhagen 1976;81:1-8.
136. Maeda K, Tanimoto K, Chihara K. Abnormal growth hormone release following luteinizing hormone releasing hormone in anorexia nervosa. Japan Journal of Psychiatry and Neurology 1987;41:41-5.
137. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, et al., Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nature Medicine 1995;1:1155-61.
138. Mantzoros CS, Flier JS, Lesem MD, Brewerton TD, Jimerson DC. Cerebrospinal fluid leptin in anorexia nervosa. Correlations with nutritional status and potential role in resistance to weight gain. Journal of Clinical Endocrinology and Metabolism 1997;82:1845-51.
139. Marshall JC, Fraser TR. Amenorrhoea in anorexia nervosa: assessment and treatment with clomiphene citrate. British Medical Journal 1971;4:590-2.
140. Marshall JC, Kelch RP. Low dose pulsatile gonadotropin-releasing hormone in anorexia nervosa: a model of human pubertal development. Journal of Clinical Endocrinology and Metabolism 1979;49:712-8.
141. Masuda A, Shibasaki T, Hotta M, Suematsu H, Shizume K. Study on the mechanism of abnormal growth hormone GH; secretion in anorexia nervosa: no evidence of involvement of a low somatomedin-C level in the abnormal GH secretion. Journal of Endocrinological Investigation 1988;11:297-302.
142. Matsubayashi S, Tamai H, Uehata S, Kobayashi N, Mori K, Nakagawa T, Kumagai LF. Anorexia nervosa with elevated serum TSH. Psychosomatic Medicine 1988;50:600-6.
143. Mazza E, Ghigo E, Goffi S, Procopio M, Imperiale E, Arvat E, Bellone J, Boghen MF, Muller EE, Camanni F. Effect of the potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone. Journal of Endocrinological Investigation 1989;12:795-8.
144. McArthur JW, Turnbull BA, Pehrson J, Bauman M, Henley K, Turner A, Evans WJ, Bullen BA, Skrinar GS. Nalmefene enhances LH secretion in a proportion of oligo-amenorrheic athletes. Acta Endocrinologica Copenhagen 1993;128:325-33.
145. McCarthy HD, McKibbin PE, Perkins AV, Linton EA, Williams G. Alterations in hypothalamic NPY and CRF in anorexic tumor-bearing rats. American Journal of Physiology 1993;264:E638-43.
146. Menzaghi F, Heinrichs SC, Pich EM, Tilders FJ, Koob GF. Functional impairment of hypothalamic corticotropin-releasing factor neurons with immunotargeted toxins enhances food intake induced by neuropeptide Y. Brain Research 1993;618:76-82.
147. Moller Madsen SM, Nystrup J. ⌊Increased incidence of anorexia nervosa in Denmark⌋. Ugeskrift for Laeger 1994;156:3291-3.
148. Moore R, Mills IH, Forster A. Naloxone in the treatment of anorexia nervosa: effect on weight gain and lipolysis. Journal of the Proceedings of the Royal Society of Medicine 1981;74:129-31.
149. Mori M, Murakami M, Satoh T, Miyashita K, Iriuchijima T, Yamada M, Inukai T, Kobayashi I. A possible direct precursor of thyrotropin-releasing hormone, pGlu-His-Pro-Gly, stimulates prolactin secretion in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 1990;71:252-5.
150. Morishita H, Takemoto M, Higuchi K, Yoshida J, Aono T. Pituitary hormone response to thyrotropin releasing hormone in secondary amenorrheic women associated with simple weight loss. Fertility and Sterility 1991;56:434-9.
151. Muller EE, Cavagnini F, Panerai AE, Massironi R, Ferrari E, Brambilla F. Neuroendocrine measures in anorexia nervosa: comparisons with primary affective disorders. Advances in Biochemical Psychopharmacology 1987;43:261-71.
152. Nakagawa K, Matsubara M, Obara T, Kubo M, Akikawa K. Responses of pituitary and adrenal medulla to insulin-induced hypoglycemia in patients with anorexia nervosa. Endocrinology Japan 1985;32:719-24.
153. Nielsen S. The epidemiology of anorexia nervosa in Denmark from 1973 to 1987: a nationwide register study of psychiatric admission. Acta Psychiatrica Scandinavica 1990;81:507-14.
154. Nussbaum MP, Blethen SL, Chasalow FI, Jacobson MS, Shenker IR, Feldman J. Blunted growth hormone responses to clonidine in adolescent girls with early anorexia nervosa. Evidence for an early hypothalamic defect. Journal of Adolescent Health Care 1990;11:145-8.
155. Ohzeki T, Egi S, Kagawa J, Nagafuchi S, Igarashi Y, Hanaki K, Ishitani N, Motozumi Wakatsuki H, Sunaguchi M. Prolonged suppression of gonadotropin secretion after weight recovery in an anorectic patient with Turner's syndrome: reduced gonadal function in anorexia nervosa is independent in part on nutrition. Hormone Metabolism Research 1989;21:626-9.
156. Paez X, Leibowitz SF. Changes in extracellular PVN monoamines and macronutrient intake after idazoxan or fluoxetine injection. Pharmacology, Biochemistry and Behavior 1993;46:933-41.
157. Phillipp E, Pirke KM, Kellner MB, Krieg JC. Disturbed cholecystokinin secretion in patients with eating disorders. Life Sciences 1991;48:2443-50.
158. Pi Sunyer X, Kissileff HR, Thornton J, Smith GP. C-terminal octapeptide of cholecystokinin decreases food intake in obese men. Physiology and Behaviour 1982;29:627-30.
159. Pirke KM, Broocks A, Wilckens T, Marquard R, Schweiger U. Starvation-induced hyperactivity in the rat: the role of endocrine and neurotransmitter changes. Neurosciences and Biobehavioral Reviews 1993;17:287-94.
160. Pirke KM, Kellner MB, Friess E, Krieg JC, Fichter MM. Satiety and cholecystokinin. International Journal of Eating Disorders 1994;15:63-9.
161. Rappaport R, Prevot C, Czernichow P. Somatomedin activity and growth hormone secretion. I. Changes related to body weight in anorexia nervosa. Acta Paediatrica Scandica 1980;69:37-41.
162. Redmond DE, Jr., Swann A, Heninger GR. Letter: Phenoxybenzamine in anorexia nervosa. Lancet 1976;2:307.
163. Reeves AG, Plum F. Hyperphagia, rage, and dementia accompanying a ventromedial hypothalamic neoplasm. Archives of Neurology 1969;20:616-24.
164. Riederer P, Toifl K, Kruzik P. Excretion of biogenic amine metabolites in anorexia nervosa. Clinica Chimica Acta 1982;123:27-32.
165. Risch SC, Janowsky DS, Judd LL, Gillin JC, McClure SF. The role of endogenous opioid systems in neuroendocrine regulation. Psychiatr Clin North American 1983;6:429-41.
166. Robinson PH, Checkley SA, Russell GF. Suppression of eating by fenfluramine in patients with bulimia nervosa. British Journal of Psychiatry 1985;146:169-76.
167. Rogacki N, Weiss GF, Fueg A, Suh JS, Pal S. Impact of hypothalamic serotonin on macronutrient intake. Annals of the New York Academic of Sciences 1989;575:619-21.
168. Rolla M, Andreoni A, Belliti D, Ferdeghini M, Cristofani R, Muller EE. Effects of cholinergic muscarinic antagonist pirenzepine on GH response to GHRH 1-40 in patients with anorexia nervosa. Endocrinologia Experimentalis 1990a;24:195-204.
169. Rolla M, Andreoni A, Belliti D, Ferdeghini M, Ferrannini E. Failure of glucose infusion to suppress the exaggerated GH response to GHRH in patients with anorexia nervosa. Biological Psychiatry 1990b;27:215-22.
170. Rolla M, Andreoni A, Belliti D, Cristofani R, Ferdeghini M, Muller EE. Blockade of cholinergic muscarinic receptors by pirenzepine and GHRH-induced GH secretion in the acute and recovery phase of anorexia nervosa and atypical eating disorders. Biological Psychiatry 1991;29:1079-91.
171. Ross R, Miell J, Freeman E, Jones J, Matthews D, Preece M, Buchanan C. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin like growth factor-I. Clinical Endocrinology 1991;35:47-54.
172. Samuels MH, Sanborn CF, Hofeldt F, Robbins R. The role of endogenous opiates in athletic amenorrhea. Fertility and Sterility 1991;55:507-12.
173. Scacchi M, Pincelli AI, Caumo A, Tomasi P, Delitala G, Baldi G, Cavagnini F. Spontaneous nocturnal growth hormone secretion in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 1997;82:3225-9.
174. Schneider BS, Monahan JW, Hirsch J. Brain cholecystokinin and nutritional status in rats and mice. Journal of Clinical Investigation 1979;64:1348-56.
175. Schwartz MW, Baskin DG, Bukowski TR, Kuijper JL, Foster D, Lasser G, Prunkard DE, Porte D, Jr., Woods SC, Seeley RJ, Weigle DS. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996;45:531-5.
176. Schweitzer I, Szmukler GI, Maguire KP, Harrison LC, Tuckwell V, Davies BM. The dexamethasone suppression test in anorexia nervosa. The influence of weight, depression, adrenocorticotrophic hormone and dexamethasone. British Journal of Psychiatry 1990;157:713-7.
177. Shibasaki T, Imaki T, Hotta M, Ling N, Demura H. Psychological stress increases arousal through brain corticotropin-releasing hormone without significant increase in adrenocorticotropin and catecholamine secretion. Brain Research 1993;618:71-5.
178. Sinha MK, Opentanova I, Ohannesian JP, Kolaczynski JW, Heiman ML, Hale J, Becker GW, Bowsher RR, Stephens TW, Caro JF. Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. Journal of Clinical Investigation 1996a;98:1277-82.
179. Sinha MK, Ohannesian JP, Heiman ML, Kriauciunas A, Stephens TW, Magosin S, Marco C, Caro JF. Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. Journal of Clinical Investigation 1996b;97:1344-7.
180. Smith GP, Greenberg D, Falusco JD. Plasma levels of cholecystokinin produced by satiating doses of exogenous CCK-8. Proceedings of the Society of Neurosciences 1995 (Abstract).
181. Soliman AT, Hassan AEI, Aref MK, Hintz RL, Rosenfeld RG, Rogol AD. Serum insulin-like growth factor I and II concentrations and growth hormone and insulin response to arginine infusions in children with proten-energy malnutrition before and after nutritional rehabilitation. Pediatric Research 1986;20:1122-30.
182. Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF. Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986;7:1189-92.
183. Stephens TW, Basinski M, Bristow PK. The role of neuropeptide Y in the antiobesity action of the obese gene. Nature 1995;377:530-2.
184. Stoving RK, Vinten J, Handberg Aa, Ebbesen EN, Hangaard J, Hansen-Nord M, Kristiansen J, Hagen C. Diurnal variation of the serum leptin concentration in patients with anorexia nervosa. Clinical Endocrinology 1998;48:761-8.
185. Stoving RK, Flyvbjerg A, Hangaard J, Fisker S, Hagen C. Low serum levels of IGF-I and IGFBP-3 in patients with anorexia nervosa are not associated with increased IGFBP-3 proteolytic activity (Abstract). IV European Congress of Endocrinology, European Federation of Endocrine Societies, Sevilla, Spain, May 1998.
186. Streat SJ, Beddoe AH, Hill GL. Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients. Journal of Trauma 1987;27:262-6.
187. Tamai H, Mori K, Matsubayashi S, Kiyohara K, Nakagawa T, Okimura MC, Walter RM, Jr., Kumagai LF, Nagataki S. Hypothalamic-pituitary-thyroidal dysfunctions in anorexia nervosa. Psychotherapy and Psychosomatics 1986;46:127-31.
188. Tamai H, Kobayashi N, Uehata S, Komaki G, Nakagawa T. Serum CCK responses to 50 gm oral glucose load in anorexia nervosa (Abstract). Fourth International Conference on Eating Disorders, 1990: p. A116.
189. Tamai H, Kiyohara K, Mukuta T, Kobayashi N, Komaki G, Nakagawa T, Kumagai LF, Aoki TT. Responses of growth hormone and cortisol to intravenous glucose loading test in patients with anorexia nervosa. Metabolism 1991;40:31-4.
190. Tepperman FS, Hirst M, Gowdey CW. A probable role for norepinephrine in feeding after hypothalamic injection of morphine. Pharmacol Biochem Behavior 1981;15:555-8.
191. Theander S. Research on outcome and prognosis of anorexia nervosa and some results from a Swedish long-term study. Int Journal of Eating Disorders 1983;2:167-74.
192. Thorner MO, Vance ML, Hartman ML, Holl RW, Evans WS, Veldhuis JD, Van Cauter E, Copinschi G, Bowers CY. Physiological role of somatostatin on growth hormone regulation in humans. Metabolism 1990;39:40-2.
193. Treasure JL, Wheeler M, King EA, Gordon PA, Russell GF. Weight gain and reproductive function: ultrasonographic and endocrine features in anorexia nervosa. Clinical Endocrinology 1988;29:607-16.
194. Turkay S, Kus S, Gokalp A, Baskin E, Onal A. Effects of protein energy malnutrition on circulating thyroid hormones. Indian Pediatrics 1995;32:193-7.
195. Vaccarino FJ, Kennedy SH, Ralevski E, Black R. The effects of growth hormone-releasing factor on food consumption in anorexia nervosa patients and normals. Biological Psychiatry 1994;35:446-51.
196. Valcavi R, Zini M, Portioli I. Triiodothyronine administration reduces serum growth hormone levels and growth hormone responses to thyrotropin-releasing hormone in patients with anorexia nervosa. Psychoneuroendocrinology 1990;15:287-95.
197. van Binsbergen CJ, Coelingh Bennink HJ, Odink J, Haspels AA, Koppeschaar HP. A comparative and longitudinal study on endocrine changes related to ovarian function in patients with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 1990;71:705-11.
198. van Binsbergen CJ, Odink J, Van der Beek EJ, Westenberg HM, Bennink HJ. Biogenic amines in anorexia nervosa: circadian rhythm in urinary excretion and influence of posture and physical task load on plasma catecholamines. Psychosomatic Medicine 1991;53:440-52.
199. Vandereycken W, Pierloot R. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta Psychiatrica Scandinavica 1982;66:445-50.
200. Veldhuis JD, Johnson ML. Cluster analysis: a simple, versatile, and robust algorithm for endocrine pulse detection. American Journal of Physiology 1986;250:E486-93.
201. Vierhapper H, Kiss A, Nowotny P, Wiesnagrotzki S, Monder C, Waldhausl W. Metabolism of cortisol in anorexia nervosa. Acta Endocrinologica Copenhagen 1990;122:753-8.
202. Vigersky RA, Loriaux DL. The effect of cyproheptadine in anorexia nervosa: A double-blind trial. In: Vigersky RA, editor. Anorexia nervosa. New York: Raven Press, 1977, p. 349-56.
203. Voerman HJ, Strack van Schijndel RJ, de Boer H, van der Veen EA, Thijs LG. Growth hormone: secretion and administration in catabolic adult patients, with emphasis on the critically ill patient. Netherlands Journal of Medicine 1992;41:229-44.
204. von Prittwitz S, Blum WF, Ziegler A, Scharmann S, Remschmidt H, Hebebrand J. Restrained eating is associated with low leptin levels in underweight females. Molecular Psychiatry 1997;2:420-2.
205. Wakeling A, DeSouza V, Beardwood CJ. Effects of administered estrogen on luteinizing hormone release in subjects with anorexia nervosa in acute and recovery stages. In: Vigersky RA editor, Anorexia nervosa. New York: Raven Press, 1977. p. 199-210.
206. Walsh BT, Roose SP, Katz JL, Dyrenfurth I, Wright L, Vande Wiele R, Glassman AH Hypothalamic pituitary-adrenal-cortical activity in anorexia nervosa and bulimia. Psychoneuroendocrinology 1987;12:131-40.
207. Warren MP, Vande Wiele RL. Clinical and metabolic features of anorexia nervosa. Am J Obstet Gynecol 1973;117:435-49.
208. West DB, Fey D, Woods SC. Cholecystokinin persistently suppresses meal size but not food intake in free feeding rats. American Journal of Physiology 1984;246:R776-87.
209. Wiersma A, Baauw AD, Bohus B, Koolhaas JM. Behavioural activation produced by CRH but not α helical CRH CRH-receptor antagonist; when microinfused into the central nucleus of the amygdala under stress-free conditions. Psychoneuroendocrinology 1995;20:423-32.
210. Woods JS, Leibowitz SF. Hypothalamic sites sensitive to morphine and naloxone: effects on feeding behavior. Pharmacol Biochem Behav 1985;23:431-8.
211. World Health Organization WHO. Clinical descriptions and guidelines. In: International Statistical Classification of Diseases and Related Health Problems ICD-10. 1992; pp. 352-3.
212. Wurtman JJ, Wurtman RJ. Drugs that enhance central serotoninergic transmission diminish elective carbohydrate consumption by rats. Life Sciences 1979;24:895-903.
213. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32.
214. Ziegler TR, Young LS, Ferrari Baliviera E, Demling RH, Wilmore DW. Use of human growth hormone combined with nutritional support in a critical care unit. Journal of Parenteral Enteral Nutrition 1990;14:574-81.
215. Ziegler TR, Rombeau JL, Young LS, Fong Y, Marano M, Lowry SF, Wilmore DW. Recombinant human growth hormone enhances the metabolic efficacy of parenteral nutrition: a double-blind, randomized controlled study. Journal of Clinical Endocrinology and Metabolism 1992;74:865-73.